Elekta's Nucletron division said it has awarded $160,000 to the American Brachytherapy Society (ABS) to fund a physician and physics residency program.
The residency-level training program in brachytherapy will be offered to radiation oncologists in the U.S. and other countries. Elekta said the money will be used to promote the use of brachytherapy as a component of efficient cancer care.
Exposure to the technology, both for young radiation oncologists in the U.S. and those visiting from abroad, is vital to the future growth of the modality, the company said. Brachytherapy is typically used for gynecological cancers, as well as for cancers of the prostate, breast, skin, and head and neck.
Nucletron has supported ABS' physician residency program for the past six years and has recently taken steps to establish a similar program for physicists, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
